^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor) + ZEN-3694 (BET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cance
Published date:
08/12/2021
Excerpt:
Concurrent treatment with ZEN-3694 and abemaciclib in WT, PALBO-R, and ABEMA-R MCF-7 cell lines, demonstrated a significant effect on the inhibition of proliferation with the calculated CI values ranging between 0.07 and 0.36...
Source:
Title:
Combination of ZEN-3694 with CDK4/6 inhibitors reverses resistance in ER-positive breast cancer
Published date:
05/15/2020
Excerpt:
The pathway analysis demonstrated that the combination of ZEN-3694 with CDK4/6 inhibitors led to the strong downregulation of multiple pathways including cell cycle regulation, signaling by Rho family GTPases, STAT3, IL6 and other pathways. We conclude that ZEN-3694 has therapeutic potential in a combination with CDK4/6 inhibitors in ER+ breast cancer patients that developed resistance to endocrine therapies and/or CDK4/6 inhibitors.
